

K-WORM CHOC SUSPENSION 400mg/10ml

Active Ingredient:

Each 10ml contains -
 Albendazole 400mg
 Preservatives -
 Methyl Hydroxybenzoate 0.2%w/v
 Propyl Hydroxybenzoate 0.03%w/v
 Sodium Benzoate 0.2%w/v

Presentation:

Bottle of 10ml.

Product Descriptions:

Brown coloured, chocolate flavoured suspension.

Pharmacology:

Albendazole is a broad-spectrum anthelmintic that exhibits vermifugal, ovcidal and larvicidal activities. Albendazole exerts its anthelmintic effect by inhibiting tubulin polymerization. This causes a cascade of metabolic disruption which includes energy depletion, immobilization and finally death. The anthelmintic activity of Albendazole is thought to be primarily intra-intestinal. When a higher dose is given, sufficient amount of Albendazole will be absorbed and can be used to treat hydatid disease and neurocysticercosis.

Albendazole is poorly absorbed from the gastrointestinal tract, but rapidly undergoes extensive first-pass metabolism. The principal metabolite, Albendazole Sulfoxide has anthelmintic activity and a plasma half-life of about 8.5 hours. Albendazole Sulfoxide is widely distributed throughout the body including into the bile and CSF. It is approximately 70% bound to plasma protein. Albendazole Sulfoxide is eliminated in the bile and only a small amount is excreted in the urine.

Indications:

For the treatment of single or mixed infestations of intestinal parasites.

Dosage and Administration:

For infestation of pinworm, whipworm, roundworm, hookworm. Adults and children above 2 years:

Take 10ml as a single dose.

Children 1 to 2 years:

Give 5ml as a single dose.

For infestation of tapeworm and threadworm

Adults and children above 2 years:

Take 10ml once daily for 3 consecutive days.

To be taken with meal.

A second course may be repeated after 2 to 3 weeks if infestations persist or recur.

Shake well before use.

Symptoms and Treatments of Overdose:

Symptoms: Gastrointestinal symptoms may occur in Albendazole overdose such as nausea, vomiting, diarrhoea and abdominal pain.

Treatment: Gastric lavage may be performed in first 2 to 3 hours after ingestion and other supportive and symptomatic treatment may be carried out if necessary.

Contraindications:

Patients with known hypersensitivity to Albendazole or other Benzimidazole derivatives.

Albendazole is known to be teratogenic and embryotoxic in some animals. Therefore it should not be administered during pregnancy or in women thought to be pregnant. Women of childbearing should take the medication within 7 days after the start of menstruation.

Precautions:

All family members and others in close contact should be treated at the same time to prevent reinfections.

If infestations persist or reoccur, please consult a doctor. Not recommended for children under 1 year unless advised by a doctor.

Should not be administered during confirmed or suspected pregnancy.

Patients treated for neurocysticercosis should receive appropriate steroid and anticonvulsant therapy to minimize cerebral hypertensive episodes.

Use in Pregnancy:

Category C: Not recommended during confirmed or suspected pregnancy as the safety for use during pregnancy has not been established.

Use in Lactation:

Use with caution during lactation as extent of excretion from breast milk is not known. Breast-feeding women should discuss this with their doctor before taking.

Interactions with Other Medicaments:

Caution should be taken when Albendazole is administered concurrently with these medications. Co-administration with Carbamazepine may decrease the efficacy of Albendazole. Whereas, when it is administered concomitantly with Cimetidine, Dexamethasone and Praziquantel, the plasma levels of the active metabolite of Albendazole may increase.

Undesirable Effects:

Albendazole is generally well-tolerated. Some undesirable effects reported include abdominal pain, nausea, vomiting, diarrhoea and headache.

Storage:

Store below 30°C. Protect from light. Keep cap tightly closed. Keep out of reach of children.

Jauhkan daripada capaian kanak-kanak.

Shelf Life:

3 years from the date of manufacture.

Registration No.: MAL19126028XCZ

X.LPWVC-1.01

Date of Revision: 19 April 2021

Product Registration Holder

POWERLIFE (M) SDN. BHD.

No.8-1, Jalan PDS 4, PD

Sunggalia Gateway, Telok

Kemang, 71050 Port Dickson,

Negeri Sembilan Darul Khusus.

Manufacturer

WINWA MEDICAL SDN. BHD.

1952, Lorong I.K.S. Bukit Minyak 3,

Taman I.K.S. Bukit Minyak,

14000 Bukit Mertajam,

Pulau Pinang, Malaysia.

Size: 55mm x 120mm

■ Black